Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen H Wright

Showing results (71-80 of 82) with videos related to

Pageof 9
Sort By:
American Journal of Physiology. Renal Physiology|July 15, 2004
Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubuleXiaohong Zhang, Carlotta E Groves, Andrew Bahn, et al.
Molecular Pharmaceutics|March 20, 2025
Computational Approaches for Predicting Drug Interactions with Human Organic Anion Transporter 4 (OAT4)Lucy Martinez-Guerrero, Patricia A Vignaux, Joshua S Harris, et al.
Acta Pharmaceutica Sinica. B|February 23, 2023
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patientsSolène Marie, Kayla L Frost, Raymond K Hau, et al.
Pharmacology Research & Perspectives|July 21, 2021
Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transportersSiennah R Miller, Joseph L Jilek, Meghan E McGrath, et al.
Angewandte Chemie (International Ed. in English)|September 17, 2008
Marine metabolites and metal ion chelation: intact recovery and identification of an iron(II) complex in the extract of the ascidian Eudistoma gilbovirideStephen H Wright, Andrea Raab, Jioji N Tabudravu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 7, 2025
Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitisDominique O Farrera, Mina M Alaaldin, Paige Lindberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2026
MegaTrans-machine learning models for drug transporters corresponding to the FDA guidancePatricia A Vignaux, Melanie Tojong, Alexander Kyu, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2026
Inhibition of equilibrative nucleoside transporters 1 and 2 by proteolysis-targeting chimeras (PROTACs)Patricia A Vignaux, Lucy J Martinez Guerrero, Renuka Raman, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2025
Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2Lucy J Martinez-Guerrero, Patricia A Vignaux, Dominique O Farrera, et al.
Molecular Pharmacology|December 2, 2020
Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian ModelingSiennah R Miller, Xiaohong Zhang, Raymond K Hau, et al.
Pageof 9

Showing results (71-80 of 82) with videos related to

Sort By:
Pageof 9
American Journal of Physiology. Renal Physiology|July 15, 2004
Relative contribution of OAT and OCT transporters to organic electrolyte transport in rabbit proximal tubuleXiaohong Zhang, Carlotta E Groves, Andrew Bahn, et al.
Molecular Pharmaceutics|March 20, 2025
Computational Approaches for Predicting Drug Interactions with Human Organic Anion Transporter 4 (OAT4)Lucy Martinez-Guerrero, Patricia A Vignaux, Joshua S Harris, et al.
Acta Pharmaceutica Sinica. B|February 23, 2023
Predicting disruptions to drug pharmacokinetics and the risk of adverse drug reactions in non-alcoholic steatohepatitis patientsSolène Marie, Kayla L Frost, Raymond K Hau, et al.
Pharmacology Research & Perspectives|July 21, 2021
Testicular disposition of clofarabine in rats is dependent on equilibrative nucleoside transportersSiennah R Miller, Joseph L Jilek, Meghan E McGrath, et al.
Angewandte Chemie (International Ed. in English)|September 17, 2008
Marine metabolites and metal ion chelation: intact recovery and identification of an iron(II) complex in the extract of the ascidian Eudistoma gilbovirideStephen H Wright, Andrea Raab, Jioji N Tabudravu, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 7, 2025
Alterations of valsartan pharmacokinetics in a rodent model of metabolic dysfunction-associated steatohepatitisDominique O Farrera, Mina M Alaaldin, Paige Lindberg, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 6, 2026
MegaTrans-machine learning models for drug transporters corresponding to the FDA guidancePatricia A Vignaux, Melanie Tojong, Alexander Kyu, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 1, 2026
Inhibition of equilibrative nucleoside transporters 1 and 2 by proteolysis-targeting chimeras (PROTACs)Patricia A Vignaux, Lucy J Martinez Guerrero, Renuka Raman, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 8, 2025
Experimental and computational approaches for evaluating molecule interactions with equilibrative nucleoside transporters 1 and 2Lucy J Martinez-Guerrero, Patricia A Vignaux, Dominique O Farrera, et al.
Molecular Pharmacology|December 2, 2020
Predicting Drug Interactions with Human Equilibrative Nucleoside Transporters 1 and 2 Using Functional Knockout Cell Lines and Bayesian ModelingSiennah R Miller, Xiaohong Zhang, Raymond K Hau, et al.
Pageof 9